Takasaki Kenji, Enatsu Kaori, Kumagami Hidetaka, Takahashi Haruo
Department of Otorhinolaryngology, Head and Neck Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1, Sakamoto, Nagasaki, 852-8501, Japan.
Eur Arch Otorhinolaryngol. 2009 May;266(5):673-6. doi: 10.1007/s00405-008-0793-7. Epub 2008 Aug 13.
In Japan, information on daily Japanese cedar pollen counts is made public during pollen season. If symptom severity and treatment outcome are predictable according to these pollen counts, management of seasonal allergic rhinitis may become more precise. The aims of the study were to evaluate the relationship between airborne pollen counts, symptom severity and treatment outcome in Japanese cedar pollinosis patients. In the randomized study, patients with moderate to most severe Japanese pollinosis were treated with fexofenadine (60 mg BD) or fexofenadine and nasal corticosteroids for 2 weeks. During the same period daily airborne pollen counts were measured. A total of 105 adult patients were enrolled. No difference of treatment efficacy was seen among groups. Detailed results of efficacy and safety were previously described elsewhere. In univariate analysis, the mean cumulative amount of airborne pollen exposure for 4 days prior to the study tended to affect symptom severity (P = 0.053) and the mean cumulative amount of airborne pollen during the treatment period tended to show difference among five treatment outcome categories (P = 0.066). In multivariate analysis, the mean cumulative amount of airborne pollen exposure for 4 days prior to the study was identified as the only significant factor of symptom severity (P = 0.0327) and cumulative amount of airborne pollen during the treatment period (P = 0.027) and allergic history (P = 0.027) were significant factors of treatment outcomes. No serious adverse effect was reported during the study. The amount of airborne pollen may be predictive of both symptom severity and treatment outcome.
在日本，日本柳杉花粉日计数信息在花粉季节会予以公布。如果根据这些花粉计数能够预测症状严重程度和治疗效果，那么季节性过敏性鼻炎的管理可能会变得更加精准。本研究的目的是评估日本柳杉花粉症患者空气中花粉计数、症状严重程度和治疗效果之间的关系。在这项随机研究中，中重度至最重度日本花粉症患者接受非索非那定（60毫克，每日两次）或非索非那定与鼻用糖皮质激素治疗2周。在此期间，对每日空气中的花粉计数进行测量。总共招募了105名成年患者。各治疗组之间未观察到治疗效果的差异。疗效和安全性的详细结果此前已在其他地方描述过。在单因素分析中，研究前4天空气中花粉暴露的平均累积量倾向于影响症状严重程度（P = 0.053），治疗期间空气中花粉的平均累积量在五个治疗结果类别中倾向于显示出差异（P = 0.066）。在多因素分析中，研究前4天空气中花粉暴露的平均累积量被确定为症状严重程度的唯一显著因素（P = 0.0327），治疗期间空气中花粉的累积量（P = 0.027）和过敏史（P = 0.027）是治疗结果的显著因素。研究期间未报告严重不良反应。空气中花粉的量可能可以预测症状严重程度和治疗效果。
